Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Neumora Therapeutics, Inc. - Common Stock
(NQ:
NMRA
)
2.930
+0.430 (+17.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neumora Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
June 20, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
May 14, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
May 07, 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in May
May 06, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
April 15, 2024
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
April 15, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P...
Via
Benzinga
Topics
Stocks
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
April 15, 2024
Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study paused; company working with FDA for resolution.
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
April 15, 2024
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.
Via
Investor's Business Daily
Why Is Mobile Global Esports (MGAM) Stock Down 18% Today?
April 15, 2024
Mobile Global Esports stock is falling on Monday after the company revealed that shares of MGAM will be delisted later this week.
Via
InvestorPlace
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
April 15, 2024
Neumora Therapeutics stock is falling on Monday as investors in NMRA shares react to a clinical trial being put on hold by the FDA.
Via
InvestorPlace
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 15, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
April 15, 2024
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!
Via
InvestorPlace
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
April 15, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 13, 2024
Via
Benzinga
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
March 13, 2024
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
March 13, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023
March 07, 2024
NMRA stock results show that Neumora Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
January 22, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
December 22, 2023
Via
Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
December 22, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...
Via
Benzinga
Topics
Stocks
7 Stocks with Strong Insider Buying: December 2023
December 17, 2023
Here are just a few of the top stocks with strong insider buying that all investors may want to watch heading into 2024.
Via
InvestorPlace
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
December 12, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 04, 2023
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today